Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...

Eli Lilly's Zepbound and Novo Nordisk's Wegovy, both priced at over $1,000 a month, have faced resistance from employers due to their high up-front costs. However, drugmakers argue that covering these ...

Novo Nordisk’s blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles ...

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Boxes of the injectable weight-loss drug Wegovy are seen in a pharmacy in Chicago on April ... The efforts by Eli Lilly and ...

There's been pressure put on Novo Nordisk to lower the cost of Ozempic and Wegovy. In late September, company CEO Lars ...

On October 22, Novo Nordisk (Novo) nominated semaglutide products, which include its popular drugs marketed as Ozempic for type 2 diabetes and ...

Kennedy has promised to "Make America Healthy Again" by tackling obesity with nutrition. Here's how he could rattle the ...

That compares with up to 16% from Novo Nordisk’s Wegovy, and up to 22.5% from Eli Lilly’s rival Mounjaro when administered alongside lifestyle interventions such as improved diet, exercise and sleep.